Clinical Trials · NCT01880424

A Phase 3, International, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Trial of Linaclotide Administered Orally for 12 Weeks to Patients With Irritable Bowel Syndrome With Constipation (IBS-C)

Name: A Phase 3, International, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Trial of Linaclotide Administered Orally for 12 Weeks to Patients With Irritable Bowel Syndrome With Constipation (IBS-C)
Creator: Peptide Science Daily
License: https://clinicaltrials.gov/about-site/terms-conditions

CompletedPhase 3Linaclotide

Phase: Phase 3
Recruitment status: Completed
Sponsor: AstraZeneca
Enrollment: 1,722
Start date: Jul 2013
Locations: 82 sites, 5 countries
Primary endpoint: 12-week Abdominal Pain/Abdominal Discomfort Weekly Responder

View Linaclotide compound reference